Vanda Pharmaceuticals Inc (VNDA)
4.575
-0.06
(-1.19%)
USD |
NASDAQ |
Apr 24, 14:43
Vanda Pharmaceuticals Revenue (Quarterly): 45.27M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 45.27M |
| September 30, 2023 | 38.82M |
| June 30, 2023 | 46.06M |
| March 31, 2023 | 62.50M |
| December 31, 2022 | 64.48M |
| September 30, 2022 | 65.32M |
| June 30, 2022 | 64.39M |
| March 31, 2022 | 60.19M |
| December 31, 2021 | 68.02M |
| September 30, 2021 | 70.10M |
| June 30, 2021 | 67.90M |
| March 31, 2021 | 62.67M |
| December 31, 2020 | 67.65M |
| September 30, 2020 | 60.31M |
| June 30, 2020 | 62.21M |
| March 31, 2020 | 58.00M |
| December 31, 2019 | 60.93M |
| September 30, 2019 | 59.48M |
| June 30, 2019 | 59.06M |
| March 31, 2019 | 47.71M |
| December 31, 2018 | 53.04M |
| September 30, 2018 | 49.14M |
| June 30, 2018 | 47.35M |
| March 31, 2018 | 43.59M |
| December 31, 2017 | 44.28M |
| Date | Value |
|---|---|
| September 30, 2017 | 41.34M |
| June 30, 2017 | 42.06M |
| March 31, 2017 | 37.42M |
| December 31, 2016 | 38.24M |
| September 30, 2016 | 38.48M |
| June 30, 2016 | 36.03M |
| March 31, 2016 | 33.26M |
| December 31, 2015 | 31.85M |
| September 30, 2015 | 28.34M |
| June 30, 2015 | 27.58M |
| March 31, 2015 | 22.15M |
| December 31, 2014 | 15.37M |
| September 30, 2014 | 14.78M |
| June 30, 2014 | 10.86M |
| March 31, 2014 | 9.143M |
| December 31, 2013 | 8.783M |
| September 30, 2013 | 8.709M |
| June 30, 2013 | 8.319M |
| March 31, 2013 | 8.068M |
| December 31, 2012 | 7.92M |
| September 30, 2012 | 8.288M |
| June 30, 2012 | 8.378M |
| March 31, 2012 | 8.141M |
| December 31, 2011 | 8.37M |
| September 30, 2011 | 7.969M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
38.82M
Minimum
Sep 2023
70.10M
Maximum
Sep 2021
60.18M
Average
62.21M
Median
Jun 2020
Revenue (Quarterly) Benchmarks
| ADMA Biologics Inc | 73.90M |
| INVO Bioscience Inc | 1.382M |
| Johnson & Johnson | 21.38B |
| Nektar Therapeutics | 23.88M |
| Invivyd Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.40M |
| Total Expenses (Quarterly) | 52.36M |
| EPS Diluted (Quarterly) | -0.04 |
| Enterprise Value | -121.87M |
| Gross Profit Margin (Quarterly) | 92.36% |
| Profit Margin (Quarterly) | -5.30% |
| Earnings Yield | 1.14% |
| Normalized Earnings Yield | 1.145 |